The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for ...

Dr. David Mahjoubi, a highly respected board-certified anesthesiologist and the founder of Ketamine Healing Clinic of Los Angeles and OC, has been recognized as a 2025 Top Patient Rated Doctor by Find ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).